articleJournal of Clinical OncologyApr 30, 2007Closed access

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

EVEric Van CutsemMPMarc PeetersSSSalvatore SienaYHYves HumbletAHAlain Hendlisz

Vrije Universiteit Brussel · Ghent University Hospital · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE: Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR). We compared the activity of panitumumab plus best supportive care (BSC) to that of BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy. PATIENTS AND METHODS: We randomly assigned 463 patients with 1% or more EGFR tumor cell membrane staining, measurable disease, and radiologic documentation of disease progression during or within 6 months of most recent chemotherapy to panitumumab 6 mg/kg every 2 weeks plus BSC (n = 231) or BSC alone (n = 232). Tumor assessments by blinded central review were scheduled from week 8 until disease progression.…

Citation impact

1,998
total citations
FWCI
84.99
Percentile
100%
References
34
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Panitumumab
  • Medicine
  • Internal medicine
  • Colorectal cancer
  • Hazard ratio
  • Response Evaluation Criteria in Solid Tumors
  • Chemotherapy
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding